Tapering and termination of immunosuppressive therapy: Systemic lupus erythematosus;Ausschleichen und Beenden von immunsuppressiven Therapien: Systemischer Lupus erythematodes

Zeitschrift fur Rheumatologie

Volumn 76, Issue 1, 2017, Pages 27-32

  Aringer, M ^a   Leuchten, N ^a   Fischer Betz, R ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Antimalarials; Flares; Glucocorticoids; Immunosuppression; Remission

Indexed keywords

CYCLOPHOSPHAMIDE; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; IMMUNOLOGIC FACTOR;

ADVERSE OUTCOME; DISEASE EXACERBATION; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; LUPUS ERYTHEMATOSUS NEPHRITIS; REMISSION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG MONITORING; EVIDENCE BASED MEDICINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROCEDURES; TREATMENT OUTCOME;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; TREATMENT OUTCOME;

EID: 85009814619     PISSN: 03401855     EISSN: 14351250     Source Type: Journal    
DOI: 10.1007/s00393-016-0258-0     Document Type: Review

References (41)

1. Mosca M, Tani C, Aringer M (2013) Withdrawal of therapy in non-renal systemic lupus erythematosus: is this an achievable goal? Clin Exp Rheumatol 31:71–S74
2. Boumpas DT, Austin HA III, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH et al (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741–745
3. The Canadian Hydroxychloroquine Study Group (1991) A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 324:150–154
4. Boumpas DT, Austin HA III, Vaughan EM, Yarboro CH, Klippel JH, Balow JE (1993) Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119:366–369
5. Faurschou M, Mellemkjaer L, Voss A, Keller KK, Hansen IT, Baslund B (2015) Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis. Rheumatology (Oxford) 54:1345–1350
6. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O’Nan P et al (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971–980
7. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, de Ramon GE, Danieli MG et al (2010) The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69:61–64
8. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH et al (2012) Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71:1771–1782
9. Knight SR, Russell NK, Barcena L, Morris PJ (2009) Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation 87:785–794
10. Aguiar B, Santos AT, Romaozinho C, Santos L, Macario F, Alves R et al (2015) Malignancy in kidney transplantation: A 25-year single-center experience in Portugal. Transplant Proc 47:976–980
11. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D et al (2011) Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365:1886–1895
12. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D et al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103–1112
13. Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M et al (2006) Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 70:732–742
14. Fischer-Betz R, Specker C, Brinks R, Aringer M, Schneider M (2013) Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. Rheumatology (Oxford) 52:1070–1076
15. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C et al (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67:195–205
16. Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA (2010) Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum 62:211–221
17. Keysser G (2011) Methotrexate toxicity. Myths and facts. Z Rheumatol 70:108–113
18. Yazici Y (2010) Long-term safety of methotrexate in the treatment of rheumatoid arthritis. Clin Exp Rheumatol 28:65–S67
19. Winzer M, Aringer M (2010) Use of methotrexate in patients with systemic lupus erythematosus and primary Sjogren’s syndrome. Clin Exp Rheumatol 28:156–S159
20. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377:721–731
21. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918–3930
22. Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW et al (2014) Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol 41:300–309
23. Bruce IN, Urowitz M, van Vollenhoven R, Aranow C, Fettiplace J, Oldham M et al (2016) Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus 25:699–709
24. Aringer M, Burkhardt H, Burmester GR, Fischer-Betz R, Fleck M, Graninger W et al (2012) Current state of evidence on ’off-label’ therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland–a consensus report. Lupus 21:386–401
25. Ryden-Aulin M, Boumpas D, Bultink I, Callejas Rubio JL, Caminal-Montero L, Castro A et al (2016) Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Sci Med 3:e000163
26. Aguiar R, Araujo C, Martins-Coelho G, Isenberg D (2016) Use of rituximab in systemic lupus erythematosus: a single center experience over 14 years. Arthritis Care Res (Hoboken). doi:10.1002/acr.22921
27. Reddy V, Martinez L, Isenberg DA, Leandro MJ, Cambridge G (2016) Pragmatic treatment of patients with Systemic Lupus Erythematosus with rituximab: Long-term effects on serum immunoglobulins. Arthritis Care Res (Hoboken). doi:10.1002/acr.22993
28. van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB (2015) Longterm safety of rituximab: final report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 years. J Rheumatol 42:1761–1766
29. Cobo-Ibanez T, Loza-Santamaria E, Pego-Reigosa JM, Marques AO, Rua-Figueroa I, Fernandez-Nebro A et al (2014) Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: A systematic review. Semin Arthritis Rheum 44(2):175–185
30. Iaccarino L, Bartoloni E, Carli L, Ceccarelli F, Conti F, de Vita S et al (2015) Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. Clin Exp Rheumatol 33:449–456
31. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P et al (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82:299–308
32. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 123:1386–1394
33. Costedoat-Chalumeau N, Dunogue B, Morel N, Le Guern V, Guettrot-Imbert G (2014) Hydroxychloroquine: a multifaceted treatment in lupus. Presse Med 43:e167–e180
34. Ruiz-Irastorza G, Khamashta MA (2008) Hydroxychloroquine: the cornerstone of lupus therapy. Lupus 17:271–273
35. van Vollenhoven RF, Aranow C, Bertsias G, Bonfa E, Cervera R, Costedoat-Chalumeau N, Dörner T, Houssiau F, Lertsrom K, Moran E, Mosca M, Navarra S, Petri M, Urowitz M, Voskuijl A, Voss A, Ward M, Werth V, Schneider M (2015) Remission in SLE: Consensus findings from a large international panel on definitions of remission in SLE (DORIS). Ann Rheum Dis 74(Suppl 2):103 (Abstract)
36. Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W, Dreher R et al (2009) Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 68:1119–1124
37. Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, Medina JA, Moran MA, Ruiz-Irastorza G (2014) Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 53:1470–1476
38. Moya FB, Pineda Galindo LF, García de la Peña M (2016) Impact of chronic glucocorticoid treatment on cardiovascular risk profile in patients with Systemic Lupus Erythematosus. J Clin Rheumatol 22:8–12
39. Listing J, Gerhold K, Zink A (2013) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 52:53–61
40. Carli L, Tani C, Spera V, Vagelli R, Vagnani S, Mazzantini M et al (2016) Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus. Lupus Sci Med 3:e000098
41. Tani C, Carli L, Vagelli R, Signorini V, Vagnani S, Totti D, Tristano M, Mosca M (2016) Glucocorticoids withdrawal in systemic lupuserythematosus: myth or reality? Ann Rheum Dis 75(Suppl 2):290 (Abstract)